IMC-EB10

IMC-EB10 (LY3012218) is an anti-FLT3 monoclonal antibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research[1][2][3][4].

Product Specifications

Product Name Alternative

LY3012218

UNSPSC

12352100

Target

Akt; FLT3; p38 MAPK; PI3K; STAT

Related Pathways

JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

References & Citations

[1]Piloto O, et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66 (9) :4843-51|[2]Erik Corcoran, et al. Abstract #2923: Preclinical pharmacokinetic and pharmacodynamic evaluation of the anti-FLT3 monoclonal antibody IMC-EB10. Cancer Res 1 May 2009; 69 (9_Supplement) : 2923.|[3]David Surguladze, et al. Synergistic Anti-Leukemic Effect of Combination Therapy with Anti-FLT3 Antibody.IMC-EB10 and Methotrexate, Blood, Volume 112, Issue 11,2008, Page 3964, ISSN 0006-4971, |[4]Li Y, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood.2004 Aug 15;104 (4) :1137-44.